The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease

Neuropharmacology

Volumn 66, Issue , 2013, Pages 187-195

  Johnson, Kari A ^a   Jones, Carrie K ^a   Tantawy, Mohammed N ^b   Bubser, Michael ^a   Marvanova, Marketa ^a,d   Ansari, M Sib ^b,c   Baldwin, Ronald M ^b,c   Conn, P Jeffrey ^a   Niswender, Colleen M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Midway College School of Pharmacy   (United States)

Author keywords

6 Hydroxydopamine; Catalepsy; Haloperidol; Metabotropic glutamate receptor (mGlu); Parkinson's disease; Reserpine

Indexed keywords

3,4 DICARBOXYPHENYLGLYCINE; DOPAMINE; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; DRUG RESPONSE; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION;

AMINOBUTYRATES; ANIMALS; BENZOATES; CATALEPSY; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID AGONISTS; FORELIMB; GLYCINE; HALOPERIDOL; INJECTIONS, INTRAVENTRICULAR; MALE; NEOSTRIATUM; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, METABOTROPIC GLUTAMATE; RESERPINE; TIME FACTORS;

EID: 84872139375     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.03.029     Document Type: Article

References (41)

1. C. Beurrier, S. Lopez, D. Revy, C. Selvam, C. Goudet, M. Lherondel, P. Gubellini, L. Kerkerian-LeGoff, F. Acher, J.P. Pin, and M. Amalric Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism Faseb J. 23 2009 3619 3628
2. S.R. Bradley, D.G. Standaert, K.J. Rhodes, H.D. Rees, C.M. Testa, A.I. Levey, and P.J. Conn Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia J. Comp. Neurol. 407 1999 33 46
3. M. Broadstock, P. Austin, M. Betts, and S. Duty Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata Br. J. Pharmacol. 2011
4. F.C. Colpaert Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat Neuropharmacology 26 1987 1431 1440
5. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237
6. P.J. Conn, G. Battaglia, M.J. Marino, and F. Nicoletti Metabotropic glutamate receptors in the basal ganglia motor circuit Nat. Rev. Neurosci. 6 2005 787 798
7. M.R. DeLong, and T. Wichmann Circuits and circuit disorders of the basal ganglia Arch. Neurol. 64 2007 20 24
8. S.P. East, S. Bamford, M.G. Dietz, C. Eickmeier, A. Flegg, B. Ferger, M.J. Gemkow, R. Heilker, B. Hengerer, A. Kotey, P. Loke, G. Schanzle, H.D. Schubert, J. Scott, M. Whittaker, M. Williams, P. Zawadzki, and K. Gerlach An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction Bioorg. Med. Chem. Lett. 20 2010 4901 4905
9. C. Goudet, B. Vilar, T. Courtiol, T. Deltheil, T. Bessiron, I. Brabet, N. Oueslati, D. Rigault, H.O. Bertrand, H. McLean, H. Daniel, M. Amalric, F. Acher, and J.P. Pin A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential Faseb J. 2012
10. E.A. Hackler, D.C. Airey, C.C. Shannon, M.S. Sodhi, and E. Sanders-Bush 5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice Neurosci. Res. 55 2006 96 104
11. K.A. Johnson, C.K. Jones, M. Marvanova, A.D. Thompson, M.N. Tantawy, R.M. Baldwin, and P.J. Conn (S)-3,4-DCPG has antiparkinsonian effects in chronic models of Parkinson's disease Neuropharmacology 55 2008 603
12. K.A. Johnson, P.J. Conn, and C.M. Niswender Glutamate receptors as therapeutic targets for Parkinson's disease CNS Neurol. Disord. Drug Targets 8 2009 475 491
13. C.K. Jones, A.E. Brady, A.A. Davis, Z. Xiang, M. Bubser, M.N. Tantawy, A.S. Kane, T.M. Bridges, J.P. Kennedy, S.R. Bradley, T.E. Peterson, M.S. Ansari, R.M. Baldwin, R.M. Kessler, A.Y. Deutch, J.J. Lah, A.I. Levey, C.W. Lindsley, and P.J. Conn Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats J. Neurosci. 28 2008 10422 10433
14. C.K. Jones, M. Bubser, A.D. Thompson, J.W. Dickerson, N. Turle-Lorenzo, M. Amalric, A.L. Blobaum, T.M. Bridges, R.D. Morrison, S. Jadhav, D.W. Engers, K. Italiano, J. Bode, J.S. Daniels, C.W. Lindsley, C.R. Hopkins, P.J. Conn, and C.M. Niswender The mGlu4 positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine A2A antagonist in preclinical rodent models of Parkinson's disease J. Pharmacol. Exp. Ther. 2011
15. C.K. Jones, D.W. Engers, A.D. Thompson, J.R. Field, A.L. Blobaum, S.R. Lindsley, Y. Zhou, R.D. Gogliotti, S. Jadhav, R. Zamorano, J. Bogenpohl, Y. Smith, R. Morrison, J.S. Daniels, C.D. Weaver, P.J. Conn, C.W. Lindsley, C.M. Niswender, and C.R. Hopkins Discovery, synthesis, and structure-Activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl) phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model J. Med. Chem. 54 2011 7639 7647
16. J. Konieczny, J. Wardas, K. Kuter, A. Pilc, and K. Ossowska The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-Aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats Neuroscience 145 2007 611 620
17. A.M. Loening, and S.S. Gambhir AMIDE: a free software tool for multimodality medical image analysis Mol. Imaging 2 2003 131 137
18. J. Logan Graphical analysis of PET data applied to reversible and irreversible tracers Nucl. Med. Biol. 27 2000 661 670
19. S. Lopez, N. Turle-Lorenzo, F. Acher, E. De Leonibus, A. Mele, and M. Amalric Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease J. Neurosci. 27 2007 6701 6711
20. S. Lopez, N. Turle-Lorenzo, T.H. Johnston, J.M. Brotchie, S. Schann, P. Neuville, and M. Amalric Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats Neuropharmacology 55 2008 483 490
21. S. Lopez, L. Jouve, N. Turle Lorenzo, L. Kerkerian-Legoff, P. Salin, and M. Amalric Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity Neurobiol. Dis. 2012
22. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
23. M. Lundblad, B. Picconi, H. Lindgren, and M.A. Cenci A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 16 2004 110 123
24. N. MacInnes, M.J. Messenger, and S. Duty Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat Br. J. Pharmacol. 141 2004 15 22
25. M.J. Marino, H. Awad-Granko, K.J. Ciombor, and P.J. Conn Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata Neuropharmacology 43 2002 147 159
26. M.J. Marino, D.L. Williams Jr.; J.A. O'Brien, O. Valenti, T.P. McDonald, M.K. Clements, R. Wang, A.G. DiLella, J.F. Hess, G.G. Kinney, and P.J. Conn Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment Proc. Natl. Acad. Sci. U S A 100 2003 13668 13673
27. M.J. Messenger, L.G. Dawson, and S. Duty Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract Neuropharmacology 43 2002 261 271
28. S. Natesan, G.E. Reckless, J.N. Nobrega, P.J. Fletcher, and S. Kapur Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models Neuropsychopharmacology 31 2006 1854 1863
29. C.M. Niswender, K.A. Johnson, Q. Luo, J.E. Ayala, C. Kim, P.J. Conn, and C.D. Weaver A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors Mol. Pharmacol. 73 2008 1213 1224
30. C.M. Niswender, K.A. Johnson, C.D. Weaver, C.K. Jones, Z. Xiang, Q. Luo, A.L. Rodriguez, J.E. Marlo, T. de Paulis, A.D. Thompson, E.L. Days, T. Nalywajko, C.A. Austin, M.B. Williams, J.E. Ayala, R. Williams, C.W. Lindsley, and P.J. Conn Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4 Mol. Pharmacol. 74 2008 1345 1358
31. N.K. Parelkar, and J.Q. Wang Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration Neurosci. Lett. 433 2008 250 254
32. O.V. Poisik, Y. Smith, and P.J. Conn D1- and D2-like dopamine receptors regulate signaling properties of group I metabotropic glutamate receptors in the rat globus pallidus Eur. J. Neurosci. 26 2007 852 862
33. L.K. Prashanth, S. Fox, and W.G. Meissner l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment Int. Rev. Neurobiol. 98 2011 31 54
34. D.J. Rubins, W.P. Melega, G. Lacan, B. Way, A. Plenevaux, A. Luxen, and S.R. Cherry Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain Neuroimage 20 2003 2100 2118
35. T. Schallert, S.M. Fleming, J.L. Leasure, J.L. Tillerson, and S.T. Bland CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury Neuropharmacology 39 2000 777 787
36. P. Sibille, S. Lopez, I. Brabet, O. Valenti, N. Oueslati, F. Gaven, C. Goudet, H.O. Bertrand, J. Neyton, M.J. Marino, M. Amalric, J.P. Pin, and F.C. Acher Synthesis and biological evaluation of 1-Amino-2- phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists J. Med. Chem. 50 2007 3585 3595
37. M.N. Tantawy, C.K. Jones, R.M. Baldwin, M.S. Ansari, P.J. Conn, R.M. Kessler, and T.E. Peterson [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot Nucl. Med. Biol. 36 2009 931 940
38. M.N. Tantawy, T.E. Peterson, C.K. Jones, K. Johnson, J.M. Rook, P.J. Conn, R.M. Baldwin, M.S. Ansari, and R.M. Kessler Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot Synapse 65 2011 1173 1180
39. N.K. Thomas, R.A. Wright, P.A. Howson, A.E. Kingston, D.D. Schoepp, and D.E. Jane (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord Neuropharmacology 40 2001 311 318
40. O. Valenti, M.J. Marino, M. Wittmann, E. Lis, A.G. DiLella, G.G. Kinney, and P.J. Conn Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse J. Neurosci. 23 2003 7218 7226
41. M.L. Wadenberg, A. Soliman, S.C. VanderSpek, and S. Kapur Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects Neuropsychopharmacology 25 2001 633 641